Literature DB >> 24266517

Human monoclonal single-chain antibodies specific to dengue virus envelope protein.

N Saokaew1, O Poungpair, A Panya, M Tarasuk, N Sawasdee, T Limjindaporn, W Chaicumpa, P Yenchitsomanus.   

Abstract

UNLABELLED: Dengue virus (DENV) infection is an arthropod-borne disease with increasing prevalence worldwide. Attempts have been made to develop therapeutic molecules for treatment for DENV infection. However, most of potentially therapeutic DENV monoclonal antibody was originated from mouse, which could cause undesirable effects in human recipients. Thus, fully human antibody is preferable for therapeutic development. Human single-chain variable fragments (HuScFv) with inhibitory effect to DENV infection were generated in this study. HuScFv molecules were screened and selected from the human antibody phage display library by using purified recombinant DENV full-length envelope (FL-E) and its domain III (EDIII) proteins as target antigens for biopanning. HuScFv molecules were then tested for their bindings to DENV particles by indirect ELISA and immunofluorescent microscopy. EDIII-specific HuScFv exhibited neutralizing effect to DENV infection in Vero cells in a dose-dependent manner as determined by plaque formation and cell ELISA. Epitope mapping and molecular docking results concordantly revealed interaction of HuScFv to functional loop structure in EDIII of the DENV E protein. The neutralizing HuScFv molecule warrants further development as a therapeutic biomolecule for DENV infection. SIGNIFICANCE AND IMPACT OF THE STUDY: No approved vaccine and specific drug for dengue virus (DENV) infection are available; thus, their developments are urgently required. The human single-chain variable antibody fragments (HuScFv) specific to DENV envelope (E) protein are potential to be developed as therapeutic biomolecules. HuScFv that bound specifically to recombinant full-length DENV E (FL-E) and its domain III (EDIII) were generated and testified for its inhibitory effect in DENV infection. EDIII-specific HuScFv inhibited DENV infection in a dose-dependent manner and has potential to be further developed as a therapeutic biomolecule for DENV infection.
© 2013 The Society for Applied Microbiology.

Entities:  

Keywords:  dengue virus; envelope protein; human single-chain variable fragments; monoclonal antibody; phage display; virus entry

Mesh:

Substances:

Year:  2013        PMID: 24266517     DOI: 10.1111/lam.12186

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  5 in total

Review 1.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

2.  Molecular docking NS4B of DENV 1-4 with known bioactive phyto-chemicals.

Authors:  Anubrata Paul; Arpana Vibhuti; Samuel Raj
Journal:  Bioinformation       Date:  2016-06-15

Review 3.  Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy.

Authors:  Tobias Unkauf; Sebastian Miethe; Viola Fühner; Thomas Schirrmann; André Frenzel; Michael Hust
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

4.  Discovery of a Biological Mechanism of Active Transport through the Tympanic Membrane to the Middle Ear.

Authors:  Arwa Kurabi; Kwang K Pak; Marlen Bernhardt; Andrew Baird; Allen F Ryan
Journal:  Sci Rep       Date:  2016-03-07       Impact factor: 4.379

Review 5.  Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.

Authors:  Philipp Kuhn; Viola Fühner; Tobias Unkauf; Gustavo Marcal Schmidt Garcia Moreira; André Frenzel; Sebastian Miethe; Michael Hust
Journal:  Proteomics Clin Appl       Date:  2016-06-21       Impact factor: 3.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.